Every year the FTC brings hundreds of cases against individuals and companies for violating consumer protection and competition laws that the agency enforces. These cases can involve fraud, scams, identity theft, false advertising, privacy violations, anti-competitive behavior and more. The Legal Library has detailed information about cases we have brought in federal court or through our internal administrative process, called an adjudicative proceeding.
H.I.G. Bayside Debt, et al., In the Matter of
The FTC required Surgery Center Holdings, Inc., known as Surgery Partners, and Symbion Holdings Corporation, to divest Symbion’s ownership interest in an ambulatory surgery center in Orange City, Florida to Dr. Mark W. Hollmann, as part of a settlement resolving charges that Surgery Partners’ $792 million purchase of Symbion would be anticompetitive. Both companies operate a large number of ambulatory surgery centers located throughout the country that sell and provide outpatient surgical services to commercial health plans and commercially insured patients. The proposed merger would have combined the only two multi-specialty ambulatory surgical centers in the Orange City/Deltona area of Florida, and would have left commercial health plans and commercially insured patients there with only one meaningful alternative to Surgery Partners’ outpatient surgical services.
Straight Talk Wireless (TracFone Wireless, Inc.)
Statement of Chairwoman Ramirez, Commissioner Brill, and Commissioner McSweeny - In the Matter of Health Discovery Corporation, and FTC v. Avrom Boris Lasarow, et al.
Dissenting Statement of Commissioner Maureen K. Ohlhausen - In the Matter of Health Discovery Corporation, and FTC v. Avrom Boris Lasarow, et al.
Boehringer Ingelheim Pharmaceuticals, Inc.
7734956 Canada Inc. (Double Shot Weight Regulator)
Zillow, Inc. and Trulia, Inc.
Statement of Commissioner Ohlhausen, Commissioner Wright, and Commissioner McSweeny Concerning Zillow, Inc/Trulia, Inc
TXVT Limited Partnership, In the Matter of
Schering-Plough Corporation, , In the Matter of
The Commission challenged Schering-Plough’s proposed $41.4 billion acquisition of Merck & Co., and required divestitures to preserve competition in markets for human and animal pharmaceuticals. The proposed consent order requires that Merck sell its interest in Merial Limited, an animal health joint venture with Sanofi-Aventis S.A., and that Schering-Plough sell its assets related to significant drugs for nausea and vomiting in humans.